Daiichi Sankyo Company, Limited: Trastuzumab Deruxtecan Type II Variation Application Validated by EMA for the Treatment of HER2 Positive Advanced Gastric Cancer
Application based on DESTINY-Gastric01 and DESTINY-Gastric02 phase 2 trials Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the European Medicines Agency (EMA)
Source: finanznachrichten.de